Evoke Pharma Inc. (EVOK)
| Bid | 2.02 |
| Market Cap | 3.24M |
| Revenue (ttm) | 10.25M |
| Net Income (ttm) | -5.35M |
| EPS (ttm) | -2.81 |
| PE Ratio (ttm) | -0.77 |
| Forward PE | 9.27 |
| Analyst | n/a |
| Ask | 2.6 |
| Volume | 7,255 |
| Avg. Volume (20D) | 17,826 |
| Open | 2.21 |
| Previous Close | 2.20 |
| Day's Range | 2.16 - 2.27 |
| 52-Week Range | 2.01 - 12.32 |
| Beta | 0.29 |
About EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine ...
2 weeks ago · proactiveinvestors.co.uk
William Hill owner Evoke falls at the first-quarter updateEvoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calendar...
2 months ago · proactiveinvestors.co.uk
William Hill owner Evoke expects earnings to beat market forecastsExpect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for 2024 will surpass market expectations, with s...